More people could count as obese under newly proposed definition — here’s what you need to know

A new diagnostic method identifies obese patients and those at risk from a health perspective much more accurately than the traditional body mass index (BMI), and its effectiveness has been confirmed by a recent study published in the journal Nature – Live Science reported.

Doctors have long criticised the exclusive use of the body mass index (BMI), as this figure – calculated as the ratio of body weight to the square of body height – does not take individual body composition into account, and therefore does not account for bone density or muscle mass either. Dr Francesco Rubino, Professor of Bariatric and Metabolic Surgery at King’s College London, led an international committee of 56 members in developing the new approach, which overcomes the shortcomings of BMI. By applying this method, fewer misdiagnoses may occur, and it will be possible to identify more accurately those patients for whom being overweight poses a genuine health risk, such as heart disease or diabetes.

According to the proposed guidelines, in addition to BMI, at least one other body measurement should be recorded that is less distorted by muscle or bone structure. These include waist circumference, the waist-to-hip ratio, and the waist-to-height ratio. As fat distribution patterns can vary between ethnic groups, the researchers have introduced threshold values for waist circumference adjusted for ethnic background. In addition, doctors must also look for 18 different obesity-related health problems and organ dysfunctions – such as cardiovascular diseases, joint pain or sleep apnoea – in patients’ medical histories.

The new framework draws a clear distinction between clinical and preclinical obesity. Clinical obesity is defined as a condition in which the accumulated adipose tissue has already actually triggered one of the 18 specified dysfunctions. In contrast, the preclinical category applies to those who, based on their body measurements, are at risk of developing the condition but have not yet experienced any organ-related problems. In practice, this means that two people with exactly the same body measurements may be classified differently depending on their general state of health. Studies show that 77–91 per cent of those in the preclinical stage do not develop clinical obesity within ten years.

By analysing Chinese, British, American and Spanish health databases, the researchers confirmed that the new category is a much more reliable predictor of mortality risk than the traditional BMI. Whilst no clear link was found between BMI alone and mortality, the risk of all-cause mortality was 69 per cent higher in those suffering from clinical obesity compared with healthy individuals.

Depending on the group under study, the introduction of the new criteria would increase the proportion of people classified as obese by 3.3 – 7.4 per cent. Under the current system, a BMI of 30 is the cut-off point, meaning that many patients who are officially classified as merely overweight are excluded from screening, even though they have already developed organ dysfunction caused by adipose tissue. Under the new definition, they too would receive a diagnosis of clinical obesity, whilst a smaller group of people with a BMI above 30 but who are completely asymptomatic would be excluded from this category.

However, the practical application of the system could pose challenges for the healthcare system. Doctors would require specialised training to carry out accurate physical measurements, and distinguishing between pre-clinical and clinical conditions could also transform prescribing practices. According to a 2025 analysis, patients who are currently eligible for weight-loss medicines under US Food and Drug Administration (FDA) guidelines may be classified as preclinical under the new system and would therefore be denied drug treatment. As a next step, the committee intends to develop a scoring system that can be used to prioritise the most severe organ dysfunctions and accurately assess the individual risk level of each patient.

Scroll to Top